[Drug sensitization in lupus erythematosus patients].
D000328:Adult; D000368:Aged; D000628:Aminophylline / Q000009:adverse effects* / Q000627:therapeutic use; D000974:Antibodies, Antinuclear; D001323:Autoantibodies; D001463:Barbiturates / Q000627:therapeutic use; D001991:Bronchitis / Q000150:complications* / Q000188:drug therapy; D004342:Drug Hypersensitivity / Q000209:etiology*; D004827:Epilepsy / Q000150:complications* / Q000188:drug therapy; D005260:Female; D005826:Genetics, Medical; D006801:Humans; D006827:Hydantoins / Q000009:adverse effects* / Q000627:therapeutic use; D008179:Lupus Erythematosus, Discoid / Q000175:diagnosis / Q000209:etiology; D008180:Lupus Erythematosus, Systemic / Q000276:immunology*; D008297:Male; D013328:Strophanthins / Q000009:adverse effects* / Q000627:therapeutic use
D000974:Antibodies, Antinuclear; D001323:Autoantibodies; D001463:Barbiturates; D006827:Hydantoins; D013328:Strophanthins; D000628:Aminophylline
Arzniemittelsensibilisierungen bei Lupus-erythematodes-Kranken.